AMOEBA (EPA:ALMIB) - Amoéba’s Board of Directors nominates Mr Bernard Ambolet as new independent director

Transparency directive : regulatory news

21/09/2018 17:45

PRESS RELEASE

Amoéba's Board of Directors nominates Mr Bernard Ambolet as new independent
director

Chassieu, September 21st, 2018 - AMOEBA (FR0011051598 - AMEBA) producer of a
biological biocide capable of eliminating bacterial risks in water, plant
protection and wound care announced today the provisional nomination of Mr
Bernard AMBOLET as an independent member of the board of Directors. Mr AMBOLET
replaces EUREKAP! company for the remainder of its term, i.e., until the
Ordinary Annual General Meeting called to review the accounts for the period
ending December 31st, 2022. This nomination will be subject to approval during
the next Annual General Meeting.

The qualification of independence has been retained by the Board of Directors
in compliance with the independence criteria defined by the MiddleNext Code.

Bernard AMBOLET

Agriculture engineer, Bernard AMBOLET spent 9 years in a technical research
institute (Arvalis - Plant institute) and 27 years within the BAYER France
group as:

* Head of Scientific Affairs
* Branch manager
* In charge of experimentations and registration of Phyto-pharmaceutical
products for the French market

In addition to his culture integrated protection skills, he has a wide
experience in management, strategic and systemic approach.

Bernard AMBOLET is a regular member of the French Academy of Agriculture and
member of the board of the AFPP (French association for Plant Protection)

Moreover, Amoéba announces the resignation- effective on May 25th, 2018-of Mrs
Marie Christine GROS FAVROT from the Board of Directors.

Within the company's governance evolution, the company is looking for new
profiles to meet Amoéba new challenges.

"I am pleased to welcome Bernard AMBOLET in the Board of Directors. Bernard
will provide the company with his expertise on both regulatory and strategic
issues on our new challenge in plant protection. I thank Eurekap! company and
more particularly its representative Guy RIGAUD who has supported the company
since 2011" declares Fabrice PLASSON, Chairman of AMOEBA.

About AMOEBA:

Amoéba's ambition is to become a major player in the treatment of bacterial
risk in the fields of water, healthcare and plant protection. Our biological
solution is an alternative to chemical products widely used today. Amoéba is
currently focusing on the market of industrial cooling towers estimated at
EUR1.7Bn (1) on a global chemical biocide market for water treatment, evaluated
at EUR21Bn (2) and on the biocontrol market for plant protection estimated
globally at EUR1.6Bn (4). In the future, the Company is looking at developing
new applications such as chronic wound care, estimated at EUR 751 million (3)
in the USA. Sales of associated products with healthcare, biocides and crop
protection are subject to the Company being granted local regulatory market
authorizations.

Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada
and in the United States, Amoéba is quoted on the compartment C of Euronext
Paris. The Company is a member of the BPI france Excellence network and is
eligible for the PEA-PME SME equity savings plan setup. More information on
www.amoeba-biocide.com.

(1): Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013
(2): Sources combined by Amoéba from water treaters, Freedonia, Eurostat et
MarketsandMarkets
(3): BCC Research, "Markets for Advanced Wound Management Technologies,"
Wellesley, MA, 2017 (4): Biopesticides Worldwide Market 2013, CPL, Wallingford,
UK

Contacts :

Amoéba
Valérie FILIATRE
Directeur administratif et Financier
04 26 69 16 00
valerie.filiatre@amoeba-biocide.com

Actifin
Ghislaine GASPARETTO Communication financière
01 56 88 11 11
ggasparetto@actifin.fr

Disclaimer

This press release contains certain forward-looking statements concerning
AMOEBA which are based on its own assumptions and hypothesis and on information
that are available to us. However, AMOEBA gives no assurance that the estimates
contained in such forward-looking statements will be verified, which estimates
are subject to numerous risks including the risks set forth in the reference
document of AMOEBA filed with the French Financial Markets Authority (Autorité
des Marchés Financiers) on April 27, 2018 (a copy of which is available on
www.amoeba-biocide.com). The forward-looking statements contained in this press
release are also subject to risks not yet known to AMOEBA or not currently
considered material by AMOEBA. The occurrence of all or part of such risks
could cause actual results, financial conditions, performance or achievements
of AMOEBA to be materially different from such forward-looking statements.

AMOEBA's latest news

28/03/2024 18:30

AMOEBA (EPA:ALMIB) - Amoéba’s Board of Directors nominates Mr Bernard Ambolet as new independent director

Transparency directive : regulatory news

AMOEBA's latest news

Other stories